Navigation Links
Patient Safety Technologies Reports Second Quarter 2012 Results
Date:8/10/2012

revenue from filling a $10 million Forward Order to our exclusive distributor, Cardinal Health.  There was no revenue reported from the delivery of Forward Order inventory during the second quarter of 2012.  Excluding the effect of the Forward Order on reported second quarter 2011 revenue, second quarter 2012 Normalized Revenue (a non-GAAP measure defined below) year over year growth was 108%.

Reported operating expenses totaled $2.4 million for the second quarter of 2012, an increase of $0.7 million compared to $1.7 million of operating expenses during the same period in 2011. The increase in operating expenses was primarily due to higher one-time costs associated with the 65 successful new customer implementations during the second quarter of 2012 as compared to 3 implementations during the second quarter of 2011.  Total estimated one-time implementation costs in the second quarter of 2012 were approximately $0.5 million, as compared to a relatively negligible amount during the second quarter of 2011.During the second quarter of 2012 the Company generated positive Adjusted Operating Income (a non-GAAP measure defined below) of $0.2 million and a GAAP operating loss of $0.5 million.  This compares with an Adjusted Operating Loss of $0.3 million and a GAAP operating loss of $0.4 million generated during the second quarter of 2011.  The primary reasons for reporting positive Adjusted Operating Income during the second quarter of 2012 as compared to an Adjusted Operating Loss during the comparable prior year period was higher reported revenues associated with the significantly larger number of customer facilities during the second quarter of 2012 versus the prior year quarter, partially offset by the higher one-time implementation expenses.

"During the second quarter of 2012 we further accelerated the strong growth we began during the first quarter, once again implementing our solution in more new facilities than in any p
'/>"/>

SOURCE Patient Safety Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
2. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
3. Watching, Reading and Listening: A New Way to Interact with Patient Information
4. Phreesia identifies over 26% of patients who require additional autism evaluation
5. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
8. New post-hoc analyses examined Neupro® effects on pain, depressed mood, apathy and fatigue in patients with Parkinsons disease
9. Patient Advocate Foundation Announces New Co-Pay Relief (CPR) Offerings for Patients Facing Health Issues Due to Electrolyte Imbalance
10. Quest Diagnostics Establishes Unique Healthcare Identifier to Improve Access to Vital Patient Health Information; 80 Million Patient IDs Created to Date
11. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... TORONTO , May 22, 2013 /PRNewswire/ ... announced three presentations demonstrating the superiority of the AE37 ... Antigen Express, Inc. ( www.antigenexpress.com ). The presentations will ... Society of Clinical Oncology (ASCO) to be held in ... June 4, 2013. The presentation entitled " ...
(Date:5/22/2013)... -- Ranbaxy Laboratories Limited (hereafter, Ranbaxy), a subsidiary ... announced on May 22 the actions that Ranbaxy ... conduct under prior management ( ... to support Ranbaxy in its efforts to address ... led to the investigations by the U.S. Department ...
(Date:5/22/2013)... 22. Mai 2013  Grifols, ein globales ... Barcelona , Spanien, präsentierte die ... höhere Dosis von PROLASTIN©-C (Alpha1-Proteinasehemmer [human]) den ... (AAT) auf ein Niveau anhebt, das innerhalb ... liegt. ATT-Mangel ist eine lebensbedrohliche, genetische Erkrankung, ...
Breaking Medicine Technology:Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 2Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 3Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 4Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 2Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 3Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 4
(Date:5/22/2013)... 22, 2013 Cedars-Sinai Heart Institute is honoring ... pioneer in modern mitral heart valve repair, Alain ... Corday, MD, International Prize in Heart Research. The ... recognize physicians and scientists conducting groundbreaking research, or ... medicine. , Carpentier is a leading ...
(Date:5/22/2013)... A new study provides neurobiological evidence for ... in people with insomnia, which may have implications ... , "Insomnia has been consistently identified as a ... Franzen, PhD, an assistant professor of psychiatry at ... in the brain circuitry underlying emotion regulation may ...
(Date:5/22/2013)... May 22, 2013 Digital Advertising Agency, ... behalf of its social media management client, Primal ... year's supply of the all-natural organic deodorant. The contest ... of the rapidly-growing start-up deodorant company based in Tampa, ... contest or sweepstakes on a Facebook page is a ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 DiscountFurnaceFilter.com ... quality merchandise ranging from furnace filters, dehumidifiers, fans, ... is excited to add Stadler Form's product line ... summer product line (fans, aroma diffusers and dehumidifiers) ... Form’s Otto Fan is the perfect combination of ...
(Date:5/22/2013)... York, NY and Troy, NY (PRWEB) May 22, ... Medicine at Mount Sinai and Rensselaer Polytechnic Institute ... educational programs, research, and development of new diagnostic ... alliance was commemorated in a signing ceremony on ... initiative to use their expertise—Rensselaer’s in engineering and ...
Breaking Medicine News(10 mins):Health News:Heart valve repair innovator receives Cedars-Sinai Heart Institute's Corday Prize in Heart Research 2Health News:Study shows that insomnia may cause dysfunction in emotional brain circuitry 2Health News:Social Media Management Firm, 21Digital, Launches National Facebook Sweepstakes for Client, Primal Pit Paste 2Health News:DiscountFurnaceFilter.com Now Offers Stadler Form Products - Providing Solutions to All Your Summer Needs 2Health News:Icahn School of Medicine at Mount Sinai and Rensselaer Polytechnic Institute Announce Academic Collaboration 2Health News:Icahn School of Medicine at Mount Sinai and Rensselaer Polytechnic Institute Announce Academic Collaboration 3Health News:Icahn School of Medicine at Mount Sinai and Rensselaer Polytechnic Institute Announce Academic Collaboration 4Health News:Icahn School of Medicine at Mount Sinai and Rensselaer Polytechnic Institute Announce Academic Collaboration 5Health News:Icahn School of Medicine at Mount Sinai and Rensselaer Polytechnic Institute Announce Academic Collaboration 6Health News:Icahn School of Medicine at Mount Sinai and Rensselaer Polytechnic Institute Announce Academic Collaboration 7
... Oct. 24 CME LLC (http://www.CMELLC.com ), ... programs,since 1978, today announced it has been granted ... as an approved sponsor of,continuing medical education for ... full approval as part of the APA,s,Continuing Education ...
... developed a new type of biodegradable nanoparticle. The ... makes it easier to target tumour tissue. These ... release of anticancer drugs. Rijcken recently gained her ... , Anticancer drugs sometimes have very harmful side ...
... used to be dogma that the brain was shut away ... outside forces of nature. But thats not how it is ... of Kevin Tracey, MD, it turns out that the brain ... the bodys inflammatory response to infection and autoimmune diseases. Understanding ...
... University of Liverpool have found that 73% of avian ... the initial infected farm, but larger outbreaks are more ... team from the Universitys Faculty of Veterinary Science and ... of Environment, Food and Rural Affairs (DEFRA) to produce ...
... Disease, ROCKVILLE, Md., Oct. 24 EntreMed, ... developing,therapeutics for the treatment of cancer and inflammatory ... Phase 2, open-label study for,Panzem(R) NCD (2ME2 or ... presented by Dr. Daniela Matei, principal investigator for,the ...
... Calif., Oct. 24 Anesiva,Inc. (Nasdaq: ANSV ) ... the markets close on Thursday, November 1, 2007 and ... day. Members of Anesiva,s,management team will discuss financial results ... overview of the company,s product pipeline, recent,events and milestones. ...
Cached Medicine News:Health News:CME LLC Granted Five-Year Full Approval by the American Psychological Association 2Health News:Nanoballs deliver drugs 2Health News:Scientists discover a direct route from the brain to the immune system 2Health News:Large avian flu outbreaks more likely to involve duck meat industry, experts find 2Health News:EntreMed Presents Results for Panzem(R) NCD Phase 2 Ovarian Cancer Study 2Health News:EntreMed Presents Results for Panzem(R) NCD Phase 2 Ovarian Cancer Study 3Health News:EntreMed Presents Results for Panzem(R) NCD Phase 2 Ovarian Cancer Study 4Health News:Anesiva to Announce Third Quarter 2007 Financial Results and Host Webcast Conference Call on November 1, 2007 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: